DOCSLIB.ORG

יומן הפטנטים והמדגמים Patents and Designs Journal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
יומן הפטנטים והמדגמים Patents and Designs Journal ב' תשע"ד 11/2013 כ"ה בכסלו התשע"ד November 28 ,3102 יומן הפטנטים והמדגמים PATENTS AND DESIGNS JOURNAL עמוד/Page פטנטים Patents בקשות שקובלו לפי סעיף Applications accepted under section 26 4 62 פטנטים שניתנו Patents granted 010 פטנטים שחודשו Patents renewed 013 פטנטים שתוקפם פקע Patents not in force 012 קודים למדינות Country codes 334 מפתחות לבקשות שהתקבלו Indices of applications accepted 302 מדגמים Designs מדגמים שנרשמו Designs registered 093 מדגמים שחודשו Designs renewed 300 מדגמים שבוטלו Designs canceled 303 כ"ה בכסלו התשע"דNovember 28, 2013- 1 ידיעות כלליות מכתבים ,מסמכים, וכו' בענייני פטנטים ומדגמים יש לשלוח אל: רשם הפטנטים והמדגמים ,גנים טכנולוגיים ירושלים, בנין מס' 5 מלחה , ירושלים. אגרות לרשות הפטנטים מתקבלות דרך שרת התשלומים הממשלתי "שוהם", או על ידי תשלום לחשבון הרשות בבנק הדואר מס' 0-54145-5 . יש להציג קבלה משרת התשלומים או מבנק הדואר יחד עם הבקשה לפעולה שעבורה האגרה שולמה. GENERAL INFORMATION Letters, documents, etc. concerning Patents and Designs should be addressed to: The Patent Authority, Jerusalem Technology Park, Building5, Malcha., Jerusalem. Fees to the Patent Office can be accepted only by payment to the Postal Bank Account of the Authority, No. 0-24145-2. The receipt of the Postal Bank must be presented to the office together with the application for the action for which the fee has been paid. זכות היוצרים בתקצירים אלה שמורה למדינת Copyright by the State of Israel. No ישראל, אין להעתיק מתקצירים אלה אלא Extracts may be published except with the ברשות לשכת הפטנטים. .permission of the Patent Office כ"ה בכסלו התשע"דNovember 28, 2013- 2 הודעה לפי סעיף 52 לחוק הפטנטים תשכ"ז - NOTICE UNDER SECTION 26 OF THE PATENTS LAW, 5727-1967 1126 הבקשות שפרטיהן מתפרסמים להלן קובלו The applications, particulars of which are set לפי סעיף 16 לחוק הפטנטים. כל המעונין out below, have been accepted pursuant to להתנגד למתן פטנט על פי בקשה מהבקשות Section 17 of the Patents Law. Any person wishing to oppose the grant of a patent on any המתפרסמות רשאי, תוך שלושה חדשים of the applications published here, may, מתאריך יומן זה, להגיש לרשם הפטנטים within three months from the date of this הודעת התנגדות לפי סעיף 00 לחוק הפטנטים journal, give to the Commissioner of Patents בדרך הקבועה בתקנה 56 ואילך לתקנות notice under Section 30 of the Patents Law, in הפטנטים, תשכ"ח – the manner prescribed in regulations 57 et seq .1121 of the Patents Regulations, 5728-1968 פרטי הבקשות במידה ויישימים מובאים לפי Particulars of the applications, where סדר זה: :applicable, are given in the following order מספר הבקשה Number of application [21] [11] שם האמצאה Title of invention [54] תאריך הבקשה Application date [22] מספר ותאריך של בקשות החוץ – מדינת Number and date of foreign [33] [32] [31] האגוד .application – convention country *סיווג בינלאומי .Int.Cl [51]* בקשה לפטנט מוסף Application for patent of addition [61] בקשת חלוקה Divisional application [62] המבקש Applicant [71] הממציא Inventor [72] מס' פרסום של בקשה הבינלאומית International Publication Number [87] מען למסירת מסמכים Address for service [74] *הערה: בקשות הפטנטים שפורסמו ביומן זה Note:, patent applications published in this* סווגו בהתאם לגרסת הסיווג הבינלאומי journal were classified according to the שהייתה בתוקף בעת הכנת הבקשות לפרסום. International Classification version that was in force when this journal was prepared. כ"ה בכסלו התשע"דNovember 28, 2013- 3 ]00[]30[ 020141 תכשירים קוטלי מזיקים המכילים PESTICIDE FORMULATIONS ]44[ סורפקטנטים של אמין מותמר באלקוקסי, CONTAINING ALKOXYLATED שיטה להכנתם ושיטה להגנה על יבולים AMINE SURFACTANTS, METHOD FOR THEIR PREPARATION AND METHOD OF PROTECTING CROPS ]33[ 03.08.1999 ]20[ 09/128950 ]23[ 05.08.1998 ]22[ US ]40[ Int. Cl.(2013.01) A01N 25//30, B01F 17//00 ]10[ SYNGENTA PARTICIPATIONS AG, SWITZERLAND ]11[ WO/2000/007709 לוצאטו את לוצאטו, ,LUZZATTO & LUZZATTO ]14[ גן תעשייה, עומר ,INDUSTRIAL PARK, OMER , ת.ד. 5055באר שבע ,P.O.B. 5352 BEER-SHEVA 84152 __________________ ]00[]30[ 142657 כתרים לילדים משרף אציטאלי ACETAL RESIN CROWNS FOR ]44[ CHILDREN ]33[ 17.04.2001 ]40[ Int. Cl.(2013.01) A61C 05//08, 13//00, 13//087 אורי-דנט בע"מ, אשקלון .URI-DENT LTD ]10[ אורי ל. זילברמן URI L. ZILBERMAN ]13[ ריינהולד כהן ושותפיו, REINHOLD COHN AND ]14[ רחוב הברזל 52א' ,PARTNERS רמת החייל ,.26A HABARZEL ST RAMAT HACHAYAL 69710 __________________ ]00[]30[ 143379 כ"ה בכסלו התשע"דNovember 28, 2013- 4 אוליגונוקליאוטיד כנגד איזופורם R של ANTISENSE AChE ]44[ אנושי ושימושיו OLIGONUCLEOTIDE AGAINST THE R ISOPHORM OF HUMAN ACHE AND USES THEREOF ]33[ 24.05.2001 ]40[ Int. Cl.(2013.01) A61K 31//7088, 48//00, A61P 21//00, 25//02, 25//28, C12N 15//11 יישום חברה לפיתוח המחקר של YISSUM RESEARCH ]10[ האוניברסיטה העברית בירושלים בע"מ, DEVELOPMENT COMPANY OF ירושלים THE HEBREW UNIVERSITY OF JERUSALEM LTD. ריינהולד כהן ושותפיו, REINHOLD COHN AND ]14[ רחוב הברזל 52א' ,PARTNERS רמת החייל ,.26A HABARZEL ST RAMAT HACHAYAL 69710 __________________ ]00[]30[ 144338 נוקלאוסיד ואולינוקלאוטיד אנלוגים ותכשירי NUCLEOSIDE AND ]44[ רוקחות המכילים אותם OLIGONUCLEOTIDE ANALOGUES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME ]33[ 10.02.2000 ]20[ 11/33863 ]23[ 12.02.1999 ]22[ JP ]40[ Int. Cl.(2013.01) C07H 19//06 ]10[ DAIICHI SANKYO COMPANY, LIMITED, JAPAN MITSUBISHI-KAGAKU FOODS CORPORATION, JAPAN ]11[ WO/2000/047599 וולף, ברגמן וגולר, ,WOLFF, BREGMAN AND GOLLER ]14[ , ת.ד. 1055ירושלים ,P.O.B. 1352 JERUSALEM 91013 __________________ ]00[]30[ 144964 תרופות לטיפול ליקויים של מסלולי סינתזת MEDICAMENTS FOR TREATING ]44[ כ"ה בכסלו התשע"דNovember 28, 2013- 5 פירימידין, המכילות 2',3',5' טריאצטילאורידין DEFICIENCIES OF PYRIMIDINE SYNTHETIC PATHWAYS, CONTAINING 2',3',5' TRIACETYLURIDINE ]33[ 23.02.2000 ]20[ 60/121588 ]23[ 23.02.1999 ]22[ US ]40[ Int. Cl.(2013.01) A61K 31//7068, C07H 19//00, 19//067 ]10[ WELLSTAT THERAPEUTICS CORPORATION, U.S.A. ]11[ WO/2000/050043 ג'יי אמ בי דייויס בן-דוד, ,JMB DAVIS BEN-DAVID ]14[ מרכז בק למדע, הרטום 1, הר חוצבים ,HARTOM ST., HAR HOTZVIM 8 , ת.ד. 45016ירושלים P.O.B. 45087 JERUSALEM 9777401 __________________ ]00[]30[ 150115 נוגדן מבודד הקושר פוליפפטידים מסוג ISOLATED ANTIBODY THAT ,RG1 ]44[ תמציד חיסוני המכיל נוגדן זה, שימושים בנוגדן ,BINDS TO RG1 POLYPEPTIDES ושיטות העושות שימוש בו AN IMMUNOCONJUGATE COMPRISING THE ISOLATED ANTIBODY AND USES AND METHODS ASSOCIATED THEREWITH ]33[ 15.12.2000 ]20[ 60/172370 ]23[ 16.12.1999 ]22[ US 193123241 1120323111 US ]40[ Int. Cl.(2013.01) A61K 38//17, 51//10, C07K 16//18 ]10[ BAYER PHARMA AKTIENGESELLSCHAFT, GERMANY ]11[ WO/2001/044291 ריינהולד כהן ושותפיו, ,REINHOLD COHN AND PARTNERS ]14[ רחוב הברזל 52א' ,.26A HABARZEL ST רמת החייל RAMAT HACHAYAL 69710 __________________ ]00[]30[ 157946 כ"ה בכסלו התשע"דNovember 28, 2013- 6 שימוש בנוגדן כנגד CD40 ונוגדן כנגד USE OF AN ANTI-CD40 CD20 ]44[ להכנת תכשירים רפואיים לטיפול במחלות ANTIBODY AND AN ANTI-CD20 סרטניות ANTIBODY FOR THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF A NEOPLASTIC DISEASE ]33[ 14.03.2002 ]20[ 60/280805 ]23[ 02.04.2001 ]22[ US ]40[ Int. Cl.(2013.01) A61K 39//395, 45//00, A61P 19//02, 37//02, C07K 16//00, 16//28 ]10[ GENENTECH, INC., U.S.A. ]11[ WO/2002/078766 ריינהולד כהן ושותפיו, ,REINHOLD COHN AND PARTNERS ]14[ רחוב הברזל 52א' ,.26A HABARZEL ST רמת החייל RAMAT HACHAYAL 69710 בקשות חלוקה מבקשה זו The applications for division ,640402 שטרם פורסמו. from this application have not yet been published __________________ ]00[]30[ 159545 תולדות הטרוביציקליים –6– חומצה DERIVATIVES OF ]44[ קרבוקסילית מותמרים, חומרי ביניים שלהן, HETEROBICYCLIC -6- תהליך להכנתן ותכשירי רוקחות המכילים אותן ,CARBOXYLIC ACID לטיפול ומניעה של זיהום מ– INTERMEDIATES THEREOF, A HCV PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR TREATMENT OR PREVENTION OF HCV INFECTION ]33[ 18.07.2002 ]20[ 60/307674 ]23[ 25.07.2001 ]22[ US 013221100 1120323110 US ]40[ Int. Cl.(2013.01) A61K 31//343, 31//381, 31//404, 31//437, A61P 01//16, C07D 20/9/08, 20/9/10, 30/7/78, 33/3/52, 40/1/04, 40/3/04, 40/5/04, 40/9/04, 41/3/04, 41/7/04, 41/7/14, 47/1/04, C07F 09//08 ]10[ BOEHRINGER INGELHEIM (CANADA) LTD., CANADA ]11[ WO/2003/010140 כ"ה בכסלו התשע"דNovember 28, 2013- 7 ריינהולד כהן ושותפיו, ,REINHOLD COHN AND PARTNERS ]14[ רחוב הברזל 52א' ,.26A HABARZEL ST רמת החייל RAMAT HACHAYAL 69710 בקשות חלוקה מבקשה זו The applications for division ,662620 שטרם פורסמו. from this application have not yet been published __________________ ]00[]30[ 160578 שרות הדרכה מרחוק ושרת REMOTE COACHING SERVICE ]44[ AND SERVER ]33[ 25.02.2004 ]40[ Int. Cl.(2013.01) G06F 17//30, H04L 12//28 ניובל-טק ידע שירותים והשקעות בע"מ, NEWVALTECH KNOWLEDGE ]10[ תל אביב SERVICES AND INVESTMENTS LTD. מרקו לוצאטו MARCO LUZZATTO ]13[ ד"ר יצחק הס ושותפיו, ,DR. YITZHAK HESS & PARTNERS ]14[ רחוב הירקון HAYARKON ST., 561 279 , ת.ד. 2451תל אביב ,P.O.B. 6451 TEL AVIV 61063 __________________ ]00[]30[ 160797 תכשירי רוקחות לצריכה דרך הפה המכילים ב– ORAL PHARMACEUTICAL ]44[ 71–אסטרדיול–3–אצטאט, שיטה להכנתם PRODUCTS CONTAINING ושימוש ב–ב–71–אסטרדיול–3–אצטאט ,17BETA-ESTRADIOL-3-ACETATE להכנתם PROCESS OF PREPARATION OF THE SAME AND USE OF 17-BETA- ESTRADIOL-3-ACETATE IN THE PREPARATION OF THE SAME ]33[ 20.12.2002 ]20[ 023748 ]23[ 21.12.2001 ]22[ US ]40[ Int. Cl.(2013.01) A61K 31//56, C07J 01//00 ]10[ WARNER CHILCOTT COMPANY, LLC, PUERTO RICO ]11[ WO/2003/055495 ריינהולד כהן ושותפיו, ,REINHOLD COHN AND PARTNERS ]14[ כ"ה בכסלו התשע"דNovember 28, 2013- 8 רחוב הברזל 52א' ,.26A HABARZEL ST רמת החייל RAMAT HACHAYAL 69710 __________________ ]00[]30[ 011001 שיטה ומערכת לפס רחב OFDM עם רשתות SYSTEM AND METHOD FOR ]44[ בתדר יחיד OFDM BROADBAND WITH SINGLE FREQUENCY NETWORKS ]33[ 10.03.2004 ]40[ Int.
Load more

Recommended publications
  • Theranos As a Legal Ethics Case Study
    Vanderbilt University Law School Scholarship@Vanderbilt Law Vanderbilt Law School Faculty Publications Faculty Scholarship 2021 How and Why Did It Go So Wrong?: Theranos as a Legal Ethics Case Study G. S. Hans Follow this and additional works at: https://scholarship.law.vanderbilt.edu/faculty-publications Part of the Legal Education Commons, and the Legal Ethics and Professional Responsibility Commons DATE DOWNLOADED: Mon May 24 12:25:08 2021 SOURCE: Content Downloaded from HeinOnline Citations: Bluebook 21st ed. G. S. Hans, How and Why Did It Go So Wrong?: Theranos as a Legal Ethics Case Study, 37 GA. St. U. L. REV. 427 (2021). ALWD 6th ed. Hans, G. G., How and why did it go so wrong?: Theranos as a legal ethics case study, 37(2) Ga. St. U. L. Rev. 427 (2021). APA 7th ed. Hans, G. G. (2021). How and why did it go so wrong?: Theranos as legal ethics case study. Georgia State University Law Review, 37(2), 427-470. Chicago 17th ed. G. S. Hans, "How and Why Did It Go So Wrong?: Theranos as a Legal Ethics Case Study," Georgia State University Law Review 37, no. 2 (Winter 2021): 427-470 McGill Guide 9th ed. G S Hans, "How and Why Did It Go So Wrong?: Theranos as a Legal Ethics Case Study" (2021) 37:2 Ga St U L Rev 427. AGLC 4th ed. G S Hans, 'How and Why Did It Go So Wrong?: Theranos as a Legal Ethics Case Study' (2021) 37(2) Georgia State University Law Review 427. MLA 8th ed.
    [Show full text]
  • Biovail Corporation U.S.$300,000,000 6.75% Convertible Subordinated Preferred Equivalent Debentures Due March 31, 2025 (U.S.$50 Principal Amount Per Security)
    Prospectus March 17, 2000 Biovail Corporation U.S.$300,000,000 6.75% Convertible Subordinated Preferred Equivalent Debentures due March 31, 2025 (U.S.$50 principal amount per security) The Company: · Interest Deferral Option: we have the right, at any time · We are an international, fully-integrated pharmaceutical and from time to time, to defer payment of interest on company that specializes in the development, the Securities by extending the interest payment period manufacture, marketing and licensing of drugs utilizing up to 20 consecutive quarters. advanced controlled-release, rapid dissolve, enhanced · Conversion Price: U.S.$60.675 per common share (equal absorption and taste masking technologies. to an initial conversion ratio of .8241 common shares per Security, subject to adjustment). · Biovail Corporation 2488 Dunwin Drive · Conversion Right: convertible at any time into our Mississauga, Ontario common shares at the applicable conversion price. Canada L5L 1J9 · Optional Redemption: beginning on March 31, 2003, we (416) 285-6000 may redeem the Securities, in whole or in part, at any time (except during an interest deferral period) at the · NYSE and TSE symbol for our common shares: BVF redemption prices stated herein, plus accrued and unpaid The Offering: interest. · Special Redemption: we may redeem the Securities, in · The Convertible Subordinated Preferred Equivalent whole or in part, at a redemption price of 106.75%, plus Debentures (the ``Securities'') are convertible accrued and unpaid interest, at any time and from time subordinated debentures bearing an interest rate, payable to time (except during an interest deferral period) prior in U.S. dollars, of 6.75% per year.
    [Show full text]
  • David Boies, Esq. BOIES, SCHILLER & FLEXNER LLP 333
    Case4:11-cv-05236-YGR Document84 Filed07/17/12 Page1 of 26 1 David Boies, Esq. BOIES, SCHILLER & FLEXNER LLP 2 333 Main Street Armonk, N.Y. 10504 3 Telephone: (914) 749-8200 Facsimile: (914) 749-8300 4 Email: [email protected] (admitted pro hac vice) 5 David W. Shapiro, Esq., SBN 219265 6 BOIES, SCHILLER & FLEXNER LLP 1999 Harrison Street, Suite 900 7 Oakland, CA 94612 Telephone: (510) 874-1000 8 Facsimile: (510) 874-1460 Email: [email protected] 9 10 Counsel for Plaintiffs, 11 UNITED STATES DISTRICT COURT 12 NORTHERN DISTRICT OF CALIFORNIA 13 OAKLAND DIVISION 14 P L L 15 R CASE NO.: CV-11-5236-YGR E N X THERANOS, INC. and ELIZABETH E L F 16 HOLMES, & SECOND AMENDED R E L COMPLAINT AND L I 17 Plaintiffs, H C JURY DEMAND S , S E 18 v. I O B 19 FUISZ PHARMA LLC, RICHARD C. 20 FUISZ, and JOSEPH M. FUISZ, 21 Defendants. 22 23 24 SECOND AMENDED COMPLAINT 25 Plaintiffs Theranos, Inc. (“Theranos”) and Elizabeth Holmes, by and 26 through their undersigned counsel, state, with knowledge of their own acts and 27 status and acts taking place in their presence, and upon information and belief as 28 to all other matters, as follows: 1 ___________________________________________________________________________________________________________________ SECOND AMENDED COMPLAINT AND JURY DEMAND Case No.: CV-11-05236-YGR Case4:11-cv-05236-YGR Document84 Filed07/17/12 Page2 of 26 1 Nature of the Action 2 1. This is an action for damages and equitable relief arising from the 3 wrongful conduct of Defendants Fuisz Pharma LLC, Richard C.
    [Show full text]
  • Contents ‐ Explanatory Notes ‐ Document 1: Letter from Defence
    Contents ‐ Explanatory notes ‐ Document 1: Letter from defence solicitor Eddie MacKechnie to Brian Murtagh of the US Department of Justice, 31 May 2000 ‐ Document 2: Letter from Murtagh to MacKechnie, 12 July 2000 ‐ Document 3: Letter from MacKechnie to Murtagh, 25 August 2000 ‐ Document 4: Letter from Murtagh to MacKechnie, 28 August 2000 ‐ Document 5: Letter from MacKechnie to Murtagh, 8 September 2000 ‐ Document 6: Letter from Robert J Eatinger, CIA Office of General Counsel to Murtagh, 12 October 2000 ‐ Document 7: Letter from Eatinger to Richard Fuisz, 13 October 2000 ‐ Document 8: Defence lawyer’s note of Fuisz’s first sworn deposition 6 December 2000 ‐ Document 9 Transcript of Fuisz’s second sworn deposition Explanatory notes Dr Richard Fuisz’s was an international businessman and deep‐cover CIA spy, who worked in the USSR and across the Middle East during the Eighties and Nineties. As well as having a very successful medical technology company, he ran training programmes for the Saudi military, supplied computers with a secret spying capability to the unwitting Soviets (via Raisa Gorbachev) and had a model agency that supplied the first Miss USSR. In May 2000, not long after the start of the Lockerbie trial, the defence lawyers got wind of Fuisz, via an associate of his, Susan Lindauer, who said that he had been based in Syria in 1988 and had irrefutable intelligence that Lockerbie was the work of the PFLP‐GC. Lindauer also said that he was the subject of a gagging order, a breach of which would result in a significant prison sentence.
    [Show full text]
  • Zero: an Investigation Into 9-11 -- Illustrated Screenplay
    ZERO: AN INVESTIGATION INTO 9-11 -- ILLUSTRATED SCREENPLAY directed by FRANCO FRACASSI, FRANCESCO TRENTO from an investigation by GIULIETTO CHIESA (Journalist, Member of the European Parliament, Member of the Commission of the European Parliament for Security and Defense), FRANCO FRACASSI, PAOLO JORMI BIANCHI, in collaboration with: SALIM CATRINA, DANIEL HOPSICKER screenplay by GIULIETTO CHIESA (Journalist, Member of the European Parliament, Member of the Commission of the European Parliament for Security and Defense), FRANCO FRACASSI, FRANCESCO TRENTO, in collaboration with PAOLO JORMI BIANCHI produced by THOMAS TORELLI for TPF TELEMACO www.zerofilm.it YOU ARE REQUIRED TO READ THE COPYRIGHT NOTICE AT THIS LINK BEFORE YOU READ THE FOLLOWING WORK, THAT IS AVAILABLE SOLELY FOR PRIVATE STUDY, SCHOLARSHIP OR RESEARCH PURSUANT TO 17 U.S.C. SECTION 107 AND 108. IN THE EVENT THAT THE LIBRARY DETERMINES THAT UNLAWFUL COPYING OF THIS WORK HAS OCCURRED, THE LIBRARY HAS THE RIGHT TO BLOCK THE I.P. ADDRESS AT WHICH THE UNLAWFUL COPYING APPEARED TO HAVE OCCURRED. THANK YOU FOR RESPECTING THE RIGHTS OF COPYRIGHT OWNERS. [Transcribed from the movie by Tara Carreon] [Woman] I'm on the 83rd floor! ... are you going to be able to get somebody up here? [9/11 Operator] We'll come up for you. [Woman] Well, there's no one here yet, and the floor is completely engulfed. We're on the floor and we can't breathe. And it's very, very, very hot. [9/11 Operator] Okay. [Woman] All I see is smoke ... I'm gonna die, aren't I? [9/11 Operator] No, no, no, no, no.
    [Show full text]
  • How Innovation Works a Bright Future Not All Innovation Is Speeding up the Innovation Famine China’S Innovation Engine Regaining Momentum
    Dedication For Felicity Bryan Contents Cover Title Page Dedication Introduction: The Infinite Improbability Drive 1. Energy Of heat, work and light What Watt wrought Thomas Edison and the invention business The ubiquitous turbine Nuclear power and the phenomenon of disinnovation Shale gas surprise The reign of fire 2. Public health Lady Mary’s dangerous obsession Pasteur’s chickens The chlorine gamble that paid off How Pearl and Grace never put a foot wrong Fleming’s luck The pursuit of polio Mud huts and malaria Tobacco and harm reduction 3. Transport The locomotive and its line Turning the screw Internal combustion’s comeback The tragedy and triumph of diesel The Wright stuff International rivalry and the jet engine Innovation in safety and cost 4. Food The tasty tuber How fertilizer fed the world Dwarfing genes from Japan Insect nemesis Gene editing gets crisper Land sparing versus land sharing 5. Low-technology innovation When numbers were new The water trap Crinkly tin conquers the Empire The container that changed trade Was wheeled baggage late? Novelty at the table The rise of the sharing economy 6. Communication and computing The first death of distance The miracle of wireless Who invented the computer? The ever-shrinking transistor The surprise of search engines and social media Machines that learn 7. Prehistoric innovation The first farmers The invention of the dog The (Stone Age) great leap forward The feast made possible by fire The ultimate innovation: life itself 8. Innovation’s essentials Innovation is gradual Innovation is different from invention Innovation is often serendipitous Innovation is recombinant Innovation involves trial and error Innovation is a team sport Innovation is inexorable Innovation’s hype cycle Innovation prefers fragmented governance Innovation increasingly means using fewer resources rather than more 9.
    [Show full text]
  • Window to the Inner Workings of The
    A WINDOW INTO THE INNER WORKINGS OF THE UNITED STATES SUSAN LINDAUER AND THE SECRET GOVERNMENT Come Carpentier de Gourdon The “mysteries” surrounding the September 11th, 2001 attacks and many other momentous events in modern American history seem to be bottomless. After so many layers have been peeled, one sees that so many more remain. Many insufficiently informed people think that those who believe in “conspiracy theories” fail to explain why no insider from the US supposedly democratic government has come out to expose the lies propagated by the successive administrations. Skeptics also wonder why the surviving victims of the 911 attacks and their families seem to meekly accept the official version instead of challenging it, on the basis of the obvious inconsistencies and impossibilities that detractors have pointed out almost since that tragic day. Let us clarify that both those objections are invalid because they are wrong. Several people working inside the US Government at various levels –including, exceptionally military officers - have spoken out against their superiors on the truth behind those terrible events, at great personal cost and risk and numerous relatives of 911 victims have joined legal and public awareness campaigns to expose the truth. Others however accepted substantial financial rewards as a price for their silence and a few have died in suspicious circumstances after being too outspoken and affirmative in their conviction that the WTC had been destroyed by controlled demolition. No single source of information on the conspiracy of 911 seems to possess all the facts, as can be logically expected in view of the systematic compartmentalization of information on the “Need to Know” basis practiced by the government, all the more so in its clandestine agencies.
    [Show full text]
  • What's Inside
    Newsletter A publication of the Controlled Release Society Volume 30 • Number 1 • 2013 What’s Inside 40th CRS Annual Meeting & Exposition Interview with Joachim Kohn Intracellular Delivery of Bioactive Molecules Using Liposomes Surface-Modified with Cell-Penetrating Peptide Octa-arginine for Improved Anticancer Activity NanoDDS Symposium Report Preclinical Sciences & Animal Health Advances Chapter News BUSINESS OPPORTUNITIES! Discover 40th Annual Meeting & Exposition of the Controlled Release Society July 21–24, 2013 Hawaii Convention Center Honolulu, Hawaii, U.S.A. Exhibit • Connect with the worldwide delivery science community with an exhibit where 1,300+ attendees can find you. • NEW! Identify your company as a first-time exhibitor from Asia or the Pacific with a tabletop in the Asia Pacific Pavilion. Make a Presentation • Present your company’s latest products, technologies, or research with a one-hour Technology Forum. • Tell about your novel technology, especially if yours is a young company, with a five-minute Soapbox presentation. Sponsor • Stand out and be recognized with a sponsorship. Support delivery science. Advertise • Invite attendees to come to your exhibit and presentations with an ad in the Annual Meeting Program Book. • “Spotlight” your company with a feature article and ad in the CRS Newsletter. Attend the Program • Gain a competitive advantage. Increase your understanding of delivery science and your customers’ needs by attending the outstanding program. Act NOW to be included in the 2013 Program Book. Contact Debby Woodard, Director of Development +1.651.994.3817 | [email protected] www.controlledreleasesociety.org/meeting Newsletter Charles Frey Vol. 30 • No. 1 • 2013 Editor Table of Contents From the Editor .................................................................................................................
    [Show full text]
  • Lindauer Affidavit
    Page 1 Page 1 1 AFFIDAVIT OF 2 SUSAN LINDAUER 3 DATE: August 13, 2012 4 SOURCE: Veterans Today, accessed May, 03, 2017. 5 http://www.veteranstoday.com/2015/05/01/911- 6 confessions-of-a-former-cia-asset/ 7 RELATED TESTIMONY: Vancouver Tribunal on 9/11, Jun. 17, 2008 8 RELATED VIDEO PRESENTATION: https://youtu.be/Nh8ZFf6S484 Susan Lindauer Resume Year Day Activity Title Jul Born to father John H. Lindauer, newspaper publisher; Alaska governor 1963 17 Republican nominee; economist; former chancellor, Univ. of Alaska, Anchorage 1985 Smith College, political science Graduate 1986 London School of Economics Graduate 1987-1988 Seattle Post-Intelligencer Reporter 1989 The Everett Herald Editor, Writer 1990-1992 U.S. News & World Report Reporter, Researcher 1993 Rep. Peter DeFazio (D-OR) Staffer 1994 Rep. Ron Wyden (D-OR) Staffer 1995 Libyan UN mission US liaison, NY C.I.A. Covert Asset 1996 Sen. Carol Moseley Braun (D-IL) C.I.A. Covert Asset, Press Secretary 1996 Iraq UN mission US liaison, NY C.I.A. Covert Asset 2002 Rep. Zoe Lofgren (D-CA) C.I.A. Covert Asset, Press Secretary ARRESTED, charged as spy for Iraqi intelligence largely on psychiatrist Stuart Mar Kleinman testimony of mental disorder and grandiose delusions; only second 2004 11 non-Arab American prosecuted by the Patriot Act by Southern District of New York, Judge Michael B. Mukasey, later appointed Attorney General, Nov. 9, 2007 2005 INCARCERATED without trial at Carswell Air Force Base psychiatric facility U.S. District (SDNY) Judge Michael B. Mukasey hearing on government request to 2006 May forcibly drug Lindauer while incarcerated Sep Judge Mukasey, released Lindauer as unfit to stand trial for mental illness; case 2006 08 reassigned to Judge Loretta Preska U.S.
    [Show full text]
  • Susan Lindauer Resume Year Day Activity Title Jul Born to Father John H
    Page 1 Page 1 1 VIDEO TRANSCRIPT OF 2 SUSAN LINDAUER 3 DATE: September 23, 2011 4 CITATION: Susan Lindauer. (Sep. 23, 2011). CIA 5 WhistleBlower Susan Lindauer EXPOSES Everything! 6 'Extreme Prejudice.' 9/11 Truth Alliance. 7 VIDEO PRESENTATION: https://youtu.be/Nh8ZFf6S484; 8 Susan Lindauer Resume Year Day Activity Title Jul Born to father John H. Lindauer, newspaper publisher; Alaska governor Republican 1963 17 nominee; economist; former chancellor, Univ. of Alaska, Anchorage 1985 Smith College, political science Graduate 1986 London School of Economics Graduate 1987-1988 Seattle Post-Intelligencer Reporter 1989 The Everett Herald Editor, Writer 1990-1992 U.S. News & World Report Reporter, Researcher 1993 Rep. Peter DeFazio (D-OR) Staffer 1994 Rep. Ron Wyden (D-OR) Staffer 1995 Libyan UN mission US liaison, NY C.I.A. Covert Asset 1996 Sen. Carol Moseley Braun (D-IL) C.I.A. Covert Asset, Press Secretary 1996 Iraq UN mission US liaison, NY C.I.A. Covert Asset 2002 Rep. Zoe Lofgren (D-CA) C.I.A. Covert Asset, Press Secretary ARRESTED, charged as spy for Iraqi intelligence largely on psychiatrist Stuart Kleinman Mar testimony of mental disorder and grandiose delusions; only second non-Arab 2004 11 American prosecuted by the Patriot Act by Southern District of New York, Judge Michael B. Mukasey, later appointed Attorney General, Nov. 9, 2007 2005 INCARCERATED without trial at Carswell Air Force Base psychiatric facility U.S. District (SDNY) Judge Michael B. Mukasey hearing on government request to 2006 May forcibly drug Lindauer while incarcerated Sep Judge Mukasey, released Lindauer as unfit to stand trial for mental illness; case 2006 08 reassigned to Judge Loretta Preska U.S.
    [Show full text]
  • Debates & Interviews
    AMALIA BABAYAN SUSANNA BAGHDASARYAN DEBATES & INTERVIEWS YEREVAN 2011 1 Երաշխավորված է ԵՊՀ Միջազգային հարաբերությունների ֆակուլտետի գիտական խորհրդի կողմից Խմբագիրներ՝ պատմ. գ. թ. Նուբար Չալըմյան Մարինա Մկրտչյան Գրախոսներ՝ բ. գ. թ. Տիգրան Միքայելյան բ. գ. թ. Աննա Պապոյան «Բանավեճեր և հարցազրույցներ» ձեռնարկը ներկայացնում է միջազգային հասարակական-քաղաքական կյանքում առտնին թեմաների շուրջ զրույցներ և քննարկումներ ականավոր քաղաքական գործիչների, դիվանագետների և գիտնականների հետ։ Նպատակն է բնօրինակ նյութի ուսումնասիրության միջոցով ուսանողներին սովորեցնել դիվանագիտական խոսքին բնորոշ մասնագիտական հաղորդակցման հմտություններ։ Դասերի կառուցվածքը և վարժությունների համակարգը միտված են հատկապես զարգացնելու մասնագիտական ոլորտում ուսանողի ինքնուրույն և ազատ շփվելու կարողությունները։ Ձառնարկը նախատեսված է միջազգային հարաբերությունների, ինչպես նաև ժուռնալիստիկայի ֆակուլտետի մագիստրատուրայի և բարձր կուրսերի ուսանողների համար։ 2 ²è²æ²´²Ü êÇñ»ÉÇ° ÁÝûñóáÕ, Ò»½ »Ýù Ý»ñϳ۳óÝáõÙ« ´³Ý³í»×»ñ & ѳñó³½ñáõÛóÝ»ñ» Ó»é- ݳñÏÁ, áñÇ ÑÇÙÝ³Ï³Ý Ýå³ï³ÏÝ ¿ ëáíáñáÕÇÝ Í³ÝáóóÝ»É Ëáë- ù³ÛÇÝ ³Ûë é»·ÇëïñÇ ë³ÑÙ³ÝÝ»ñáõÙ Ù»ñûñÛ³ ¹Çí³Ý³·»ïÝ»ñÇ, µ³ñÓñ å³ßïáÝ۳ݻñÇ & ·ÇïݳϳÝÝ»ñÇ û·ï³·áñÍ³Í ³Ý·É»ñ»- ÝÇ É»½í³-á×³Ï³Ý ³é³ÝÓݳѳïÏáõÃÛáõÝÝ»ñÇ Ñ»ï, áñáÝó áõëáõÙ- ݳëÇñáõÃÛáõÝÁ ÏÝå³ëïÇ ëáíáñáÕÇ Ñ³Õáñ¹³Ïó³Ï³Ý É»½íÇ ÑÙïáõÃÛáõÝÝ»ñÇ Ùß³ÏÙ³ÝÝ áõ ½³ñ·³óÙ³ÝÁ£ ¶ñùáõÙ ¹áõù Ï·ïÝ»ù ³Ï³Ý³íáñ Ù³ñ¹Ï³Ýó Ñ»ï í»ñçÇÝ ÙÇ ù³- ÝÇ ï³ñÇÝ»ñÇ ÁÝóóùáõÙ ³Ýóϳóñ³Í å³ßïáÝ³Ï³Ý µ³Ýí»×»ñÇ & ѳñó³½ñáõÛóÝ»ñÇ µÝûñÇÝ³Ï ³ñӳݳ·ñáõÃÛáõÝÝ»ñÇ Ïñ׳ï Ý»ñϳ۳óñ³Í ï³ñµ»ñ³ÏÝ»ñÁª ù³Õí³Í ѳٳó³ÝóÇó£ ÜÛáõÃÁ ݳ˳ï»ëí³Í ¿ 100-120 ų٠áõëáõóÙ³Ý
    [Show full text]
  • Bad Blood : Secrets and Lies in a Silicon Valley Startup / John Carreyrou
    THIS IS A BORZOI BOOK PUBLISHED BY ALFRED A. KNOPF Copyright © 2018 by John Carreyrou All rights reserved. Published in the United States by Alfred A. Knopf, a division of Penguin Random House LLC, New York, and distributed in Canada by Random House of Canada, a division of Penguin Random House Canada Limited, Toronto. www.aaknopf.com Knopf, Borzoi Books, and the colophon are registered trademarks of Penguin Random House LLC. Library of Congress Cataloging-in-Publication Data Names: Carreyrou, John, author. Title: Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou. Description: First Edition. | New York : Knopf, 2018. Identifiers: LCCN 2018000263 | ISBN 9781524731656 (hardback) | ISBN 9781524731663 (ebook) Subjects: LCSH: Theranos (Firm)—History. | Hematologic equipment industry—United States. | Fraud—United States. | BISAC: BUSINESS & ECONOMICS / Entrepreneurship. | BUSINESS & ECONOMICS / Finance. | TECHNOLOGY & ENGINEERING / Biomedical. Classification: LCC HD9995.H423 U627 2018 | DDC 338.7/681761—dc23 LC record available at https://lccn.loc.gov/2018000263 Ebook ISBN 9781524731663 Cover design by Tyler Comrie v5.2_r1 ep Contents Cover Title Page Copyright Dedication Author’s Note Prologue 1. A Purposeful Life 2. The Gluebot 3. Apple Envy 4. Goodbye East Paly 5. The Childhood Neighbor 6. Sunny 7. Dr. J 8. The miniLab 9. The Wellness Play 10. “Who Is LTC Shoemaker?” 11. Lighting a Fuisz 12. Ian Gibbons 13. Chiat\Day 14. Going Live 15. Unicorn 16. The Grandson 17. Fame 18. The Hippocratic Oath 19. The Tip 20. The Ambush 21. Trade Secrets 22. La Mattanza 23. Damage Control 24. The Empress Has No Clothes Epilogue Acknowledgments Notes About the Author For Molly, Sebastian, Jack, and Francesca Author’s Note This book is based on hundreds of interviews with more than 150 people, including more than sixty former Theranos employees.
    [Show full text]